Prediction of local recurrence in ductal carcinoma in situ: Clinical validation of DCIS score

6^th International Conference on Biomarkers & Clinical Research

August 31-September 02, 2015 Toronto, Canada

Sharon Nofech Mozes

University of Toronto, Canada

Scientific Tracks Abstracts: J Mol Biomark Diagn

Abstract :

The Ontario DCIS population-based study identified women with pure DCIS from 1994-2003. Clinical validation of DCIS Score (DS) (Rakovitch, SABCS2014) showed prediction of risk of an ipsilateral local recurrence (LR). Centrally reviewed pathology for: Focality, size, grade, subtype, comedo necrosis & clear margins, (CM=no ink on tumor) will be presented. The DS was obtained by quantitative RT-PCR. Cox modeling was used to determine the relationship between independent co-variates, DS (hazard ratio (HR)/50 units) & LR. DCIS score was evaluated in 718 women w/DCIStx with BCS alone (571 w/CM). With a median follow-up of 9.4 years, 100 BCS alone w/CM cases developed LR (44 DCIS, 57 invasive). In the primary analysis, among 571 patients treated by BCS alone with CM the continuous DS was significantly associated with LR in ER+patients (HR 2.26; 95%CI 1.41, 3.59; P=0.001) and in all patients (HR 2.15; 95%CI 1.43, 3.22; P=<0.001). The results of univariable and multivariable analyses, hazard ratios for factors associated with in situ and distance local recurrence will be presented. DCIS Scores were widely distributed within each subgroup defined by the clinical and pathology characteristics. For DCIS patients treated with BCS alone the DCIS Score, focality, tumor size and histologic subtype provide independent LR information. Patients with low DCIS score and non-multifocal disease may be considered for BCS alone.

Biography :

Sharon Nofech Mozes obtained her medical degree from Tel Aviv University, Israel. She completed breast and gynecologic pathology fellowships at the University of Toronto, Canada. She is an Associate Professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. She is the breast pathology lead in Sunnybrook. She is a member of the institutional Research Ethics Board. Her main research interest is ductal carcinoma in situ. She has authored or co-authored more than 55 peer reviewed manuscripatients, including provincial guidelines for hormone receptor testing in breast cancerand biomarkers synoptic report for the CAP.

Email: Sharon.Nofech-Mozes@sunnybrook.ca